Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease

被引：0
|
作者：
Fiorino, G. [1 ]
Ruiz-Aguello, M. B. [2 ]
Maguregui, A. [2 ]
Nagore, D. [2 ]
Radice, S. [1 ]
Gilardi, D. [1 ]
Correale, C. [1 ]
Allocca, M. [1 ]
Furfaro, F. [1 ]
Alfieri, M. [1 ]
Martinez, A. [2 ]
Danese, S. [1 ,3 ]
机构：
[1] Humanitas Clin & Res Ctr, Dept Gastroenterol, Milan, Italy
[2] Progenika Biopharma SA, R&D Dept, Derio, Spain
[3] Humanitas Univ, Dept Biomed Sci, Milan, Italy
来源：
JOURNAL OF CROHNS & COLITIS | 2017年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P633
引用
收藏
页码：S403 / S404
页数：2
相关论文
共 50 条
  • [21] Infliximab biosimilar CT-P13 in Crohn's disease
    Gecse, Krisztina B.
    D'Haens, Geert R.
    LANCET, 2019, 393 (10182): : 1671 - 1672
  • [22] Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
    Yoo, Dae Hyun
    Prodanovic, Nenad
    Jaworski, Janusz
    Miranda, Pedro
    Ramiterre, Edgar
    Lanzon, Allan
    Baranauskaite, Asta
    Wiland, Piotr
    Abud-Mendoza, Carlos
    Oparanov, Boycho
    Smiyan, Svitlana
    Kim, HoUng
    Lee, Sang Joon
    Kim, SuYeon
    Park, Won
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (02) : 355 - 363
  • [23] Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13
    Parigi, Tommaso Lorenzo
    D'Amico, Ferdinando
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (01) : 37 - 46
  • [24] Infliximab therapeutic drug monitoring test validated for measuring CT-P13 and SB2 biosimilars
    Ruiz-Aguello, M. B.
    Maguregui, A.
    Martinez, A.
    Nagore, D.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S299 - S299
  • [25] Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis
    Gisondi, P.
    Virga, C.
    Piaserico, S.
    Meneguzzo, A.
    Odorici, G.
    Conti, A.
    Girolomoni, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (02) : 397 - 398
  • [26] Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series
    Yun-Seong Kang
    Hyoung Ho Moon
    Seung Eun Lee
    Yun Jeong Lim
    Hyoun Woo Kang
    Digestive Diseases and Sciences, 2015, 60 : 951 - 956
  • [27] Cross-switch from CT-P13 to sb2 infliximab biosimilars in patients with chronic plaque psoriasis
    Gisondi, P.
    Virga, C.
    Girolomoni, G.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 29 - 29
  • [28] Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13
    Park, Won
    Miranda, Pedro
    Brzosko, Marek
    Wiland, Piotr
    Gutierrez-Urena, Sergio
    Mikazane, Helena
    Lee, Yeon-Ah
    Smiyan, Svitlana
    Lim, Mie-Jin
    Kadinov, Vladimir
    Abud-Mendoza, Carlos
    Son, YoungKi
    Yoo, Dae-Hyun
    Braun, Juergen
    ARTHRITIS AND RHEUMATISM, 2013, 65 (12): : 3326 - 3326
  • [29] Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series
    Kang, Yun-Seong
    Moon, Hyoung Ho
    Lee, Seung Eun
    Lim, Yun Jeong
    Kang, Hyoun Woo
    DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (04) : 951 - 956
  • [30] Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
    Jung, Yoon Suk
    Park, Dong Il
    Kim, Young Ho
    Lee, Ji Hyun
    Seo, Pyoung Ju
    Cheon, Jae Hee
    Kang, Hyoun Woo
    Kim, Ji Won
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 (12) : 1705 - 1712
12345